Jounce Therapeutics to Present at Cowen and Company 37th Annual Health Care Conference
February 28 2017 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Richard Murray, Ph.D., chief executive officer of Jounce, will
present a company overview at the Cowen and Company 37th Annual
Health Care Conference at 10:40 a.m. E.T. on Tuesday, March 7, 2017
in Boston.
A live webcast of the presentation will be
available by visiting the Investors and Media section of Jounce’s
website at http://ir.jouncetx.com. A replay of the webcast will be
archived for 30 days following the presentation.
About Jounce Therapeutics Jounce
Therapeutics, Inc. is a clinical stage immunotherapy company
dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and
provide long‑lasting benefits to patients. Through the use of its
Translational Science Platform, Jounce first focuses on specific
cell types within tumors to prioritize targets, and then identifies
related biomarkers designed to match the right therapy to the right
patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal
antibody that binds to and activates ICOS and is currently in a
Phase 1/2 trial. For more information, please visit
http://jouncetx.com/.
Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact:
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Apr 2024 to May 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From May 2023 to May 2024